CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting AstraZeneca’sCALQUENCE® in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for…
Element Biosciences Introduces VITARI™, Redefining What High-Throughput Sequencing Makes Possible Element Biosciences Inc. today announced VITARI, the first ever high-throughput benchtop sequencing system capable of delivering a high-quality whole genome at $100. With the introduction of VITARI, Element now offers a…
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch ImmunityBio, Inc. a commercial-stage immunotherapy company, today announced a partnership with Accord Healthcare to provide access to ANKTIVA® (nogapendekin alfa inbakicept) in combination…
Henry Schein One Launches Image Verify, Another Transformative Step Towards Achieving the Cleanest Claims in the Industry Henry Schein One, the market leader in dental practice management systems, today announced the launch of AI-driven Image Verify, the latest innovation in…
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine Merck known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world’s top-ranked hospital system, today announced a research and…
Icon Group Deploys ChartCheck Adaptive Across Australia as Radformation Secures USFDA 510(k) Clearance Radformation, a leading provider of intelligent automation solutions for radiation oncology, and Icon Group (Icon), a leading global integrated cancer care provider, today announced the initial deployment of ChartCheck Adaptive,…
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline KalVista Pharmaceuticals, Inc. today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients…
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed in a Phase 1 clinical…
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi…
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug…
Regional Dermatology Joins Epiphany Dermatology Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in Missouri through its partnership with Regional Dermatology, LLC. Founded in 2010 by Sarah Jensen, M.D.,…
Corazon and Columbia HeartSource Announce Partnership Offering First-of-its-Kind Open-Heart Surgery Accreditation Columbia HeartSource, an extension of Columbia University Irving Medical Center’s Department of Surgery and Division of Cardiology and Corazon, a national leader in strategic program development for cardiovascular services, today…
